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Copyright © 2011 JCBN 2011 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. Lansoprazole is effective in healing non steroidal anti inflammatory
drugs induced ulcers, and antioxidant properties have been
thought to play a key role in healing ulcers. We hypothesize that
lansoprazole exerts a cytoprotective effect by inhibiting reactive
oxygen species leakage from mitochondria and lipid peroxidation.
We pretreated gastric epithelial RGM1 cells with lansoprazole and
then treated them with indomethacin in vitro. We found that the
lansoprazole pretreatment significantly reduced cellular injury,
maintained mitochondrial transmembrane potential, and decreased
lipid peroxidation. Furthermore, the signal intensity of the electron
spin resonance spectrum of the indomethacin treated mitochon 
dria which were pretreated with lansoprazole showed considerable
reduction compared to those without the lansoprazole pretreat 
ment. These results suggest that lansoprazole reduced superoxide
production in the mitochondria of indomethacin treated cells, and
subsequently inhibited lipid peroxide and cellular injury in gastric
epithelial cells.
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Introduction Lansoprazole belongs to the class of proton pump inhibitors
(PPIs) which are effective in healing non-steroidal anti-
inflammatory drugs (NSAIDs)-induced ulcers and preventing
their recurrence in patients requiring ongoing NSAIDs therapy.(1,2)
Lansoprazole has been thought to prevent NSAIDs-induced
ulcers and cellular injury through an effect that inhibits acid
secretion, but this is not the only important effect. A meta-analysis
showed that H2-receptor antagonists (H2RAs) which also inhibited
acid secretion did not significantly reduce the risk of symptomatic
ulcers among patients receiving NSAIDs.(3)
The difference between PPIs and H2RAs can be attributed to
the strength of acid suppression, while the cytoprotective effects
of lansoprazole have been reported, as well as acid secretion
inhibitory effects.(4,5)
NSAIDs-induced gastric injuries have been reported to be
derived by their pharmacological effects by inhibiting cyclo-
oxygenase (COX) from depleting mucosal prostaglandin E2
(PGE2) concentration. Lansoprazole has not been reported to
influence PGE2 mucosal concentration.(6) Therefore, the cyto-
protective effect should be derived from the other physiological
mechanisms without depletion of PGE2.
There were several reports that NSAIDs treatment involved
both the uncoupling of mitochondrial oxidative phosphorylations
and the inhibition of the electron transport chain with various
kinds of cells or isolated mitochondria.(7) This results in depletion
of intracellular ATP and the generation of reactive oxygen species
(ROS).(8–10) ROS may lead to lipid peroxidation and apoptosis by
releasing cytochrome c.(11,12)
We hypothesize that lansoprazole exerts a cytoprotective effect
by inhibiting ROS leakage from mitochondria and lipid per-
oxidation. Lansoprazole has been reported to decrease the tissue
oxidative stress induced by NSAIDs treatment.(4,13) The protective
effects of lansoprazole against NSAIDs-induced oxidative stresses
may be derived from a direct reaction which decreases mitochon-
drial ROS production. However, there has been no report to
confirm which kind of ROS can be involved after the NSAIDs
treatment, or to confirm the details of lansoprazole’s pharmaco-
logical effects for NSAIDs-induced tissue oxidative stresses.
In this study, we elucidated which kind of ROS was generated
and whether or not lansoprazole showed a direct protective effect
for ROS generation after indomethacin, a NSAID treatment. We
examined both indomethacin-induced ROS production and cellular
tissue peroxidation with and without lansoprazole pretreatment
using our established normal gastric epithelial cell-line, RGM1.
In particular, we confirmed the kind of ROS produced from
indomethacin-treated cellular mitochondria with both an electron
spin resonance (ESR) technique and a new spin trapping reagent 5-
(2,2-Dimethyl-1,3-propoxy cyclophosphoryl)-5-methyl-1-pyrroline
N-oxide (CYPMPO). Using this technique, we also examined the
effects of lansoprazole on mitochondrial ROS generation after the
indomethacin treatment.
Materials and Methods
Cell culture. The previously established gastric epithelial cell
line, RGM1, was reobtained by our laboratory from RIKEN
BioResource Center (Tsukuba, Japan). Cells were grown in a 1:1
mixture of both Dulbecco’s modified Eagle medium and Ham’s
F-12 medium (DMEM/F12; Cosmo Bio, Tokyo, Japan) supple-
mented with 10% fetal calf serum (FCS; Gibco, Grand Island, NY)
and 2 mM glutamine at 37°C in a humidified incubator with 5%
CO2.
Reagents. Indomethacin was purchased from WAKO Co.
(Osaka, Japan), Lansoprazole was obtained from Takeda Pharma-
ceutical Co. (Osaka, Japan), prostaglandin E2 was purchased from




was purchased from Cosmo Bio Co., Ltd., FCS was purchased
from Gibco BRL, Tetra Color ONE® cell proliferation assay kit
from Seikagaku (Tokyo, Japan), Diphenyl-1pyrenylphosphine
(DPPP) and 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazo-
lylcarbocyanine iodide (JC-1) from Dojindo (Kumamoto, Japan), 5-
(2,2-Dimethyl-1,3-propoxy cyclophosphoryl)-5-methyl-1-pyrroline
N-oxide (CYPMPO) from Radical Research Inc. (Tokyo, Japan).
All other chemicals were reagent grade.
MnSOD c DNA transfection. The pCR3.1-Uni plasmid
(Invitrogen, Carlsbad, CA) containing a sense human MnSOD
(manganese superoxide dismutase) cDNA insert was kindly
supplied by Dr. Akashi (National Institute of Radiological Sciences,
Chiba, Japan). Sequence analysis of the MnSOD gene in the
construct showed that the sequence was identical to that of the
gene with GenBank Accession No. Y00472, except that C at
position 113 was changed to T, and C at position 529 was changed
to G, which caused changes from alanine to valine and glutamine
to glutamic acid, respectively. The RGM1 cells were transfected
using the LipofectamineTM 2000 reagent transfection system
(Invitrogen) in accordance with the manufacturer’s instructions.
Briefly, cells were plated onto 60-mm dishes and incubated for
24 h before transfection at 80% confluence. The cells were stably
transfected with 5 µg of pCR3.1-Uni plasmids containing a sense
human MnSOD cDNA insert, and linearized by Sca I, in a serum-
free DMEM/F12, and five hours after transfection, the medium
was changed to DMEM/F12 containing 10% fetal bovine serum.
The controls were transfected with pCR3.1-Uni plasmids without
a human MnSOD cDNA (vector alone) insert and linearized by
Sca I. Stable clones of both MnSOD and control plasmid trans-
fectants were selected with Geneticin (Life Technologies, Carlsbad,
CA) at a final concentration of 500 µg/ml. Selected cellular clones
that expressed MnSOD (MnSOD-4, -6 and -8), selectable marker
alone (vector), and the parental cell (RGM1) were used in all of
the experiments. Selected clones were routinely maintained in
DMEM containing 10% fetal bovine serum (JRH Biosciences,
Lenexa, KS) and 500 µg/ml Geneticin at 37°C in humidified air
containing 5% CO2.
Cytotoxicity assay. Cellular injury was examined with the
Tetra Color One assay kit according to the manufacturer’s
instructions. Cells at a concentration of 105 cells/ml were placed
on a microtiter plate well. Twenty-four hours later, cells were
washed with phosphate buffered saline (PBS; Gibco) and pre-
treated with lansoprazole, omeprazole, and control media for 24 h,
respectively, then washed with PBS and treated with indo-
methacin. After 18 h incubation, then washed with PBS and treated
with serum-free media containing 10 µl Tetra Color One for 1 h.
The absorbance of each well at 450 nm was measured with a
multimode plate reader (DTX 880; Beckman Coulter, Fullerton,
CA).
Cellular injury was also examined by MnSOD-overexpressed
cells (MnSOD-4, -6 and -8). Cells were pretreated with lansopra-
zole for 24 h, then washed with PBS and treated with indo-
methacin. After 24 h incubation, they were washed with PBS and
treated with serum-free media containing 10 µl Tetra Color One
for 1 h. The absorbance of each well was measured with the same
methods mentioned above.
Detection of lipid peroxidation. Diphenyl-1-pyrenylphos-
phine (DPPP) reacts specifically with hydroperoxides and hydrogen
peroxide that are generated within cell membranes to give fluores-
cent diphenyl-1-pyrenylphosphine oxide (DPPP oxide), which
emits fluorescence with excitation and emission wavelengths of
351 and 380 nm, respectively. Cells incubated in medium on a slide
chamber were pretreated with lansoprazole for 24 h and then
treated with indomethacin for 18 h. After washing with PBS and
incubating with DMEM/F12 containing 10 µM DPPP for 30 min,
cellular fluorescent images were observed and their intensities
were measured with a chilled CCD camera (AxioCam color, ZEISS,
Germany)-mounted epi-fluorescence microscope (Axiovert135M,
ZEISS) connected to an image analyzing system (Axio Vision,
ZEISS).
Mitochondrial membrane potential detection. Mitochon-
drial membrane potential was measured with JC-1. In healthy
cells, JC-1 accumulates as aggregates in the mitochondria which
stain red, whereas, if the mitochondrial membrane potential
collapses, JC-1 exists in monomeric form and stains the cytosol
green. The aggregate red form has an absorption/emission maxima
of 585/590 nm. The green monomeric form has an absorption/
emission maxima of 510/527 nm. Cells at a concentration of
105 cells/ml were placed on a microtiter plate well, and cells were
pretreated with lansoprazole for 24 h, then washed with PBS and
treated with indomethacin. After 18 h incubation, cells were
washed with PBS and incubated with serum-free media containing
JC-1. After 15 min incubation, the cells were washed with PBS
and analyzed by fluorescence plate reader (DTX-880; Bechman
Coulter, Fullerton, CA).
Electron spin resonance spectroscopy. Reactive oxygen
species were measured by ESR. Cells were pretreated with
lansoprazole for 24 h, then washed with PBS. Then, cells were
treated with indomethacin for 4 h. After administration of reagents,
cells were gently scraped off the dish, and isolated to mitochon-
dria. A Mitochondria Isolation Kit for Cultured cells (Pierce
Biotechnology, Inc. Rockford, IL) was used for this procedure.
The pellet of mitochondria was resuspended with 5 mM respiratory
substrates (succinate, glutamate and malate), 5 mM NADH and
10 mM CYPMPO. The reaction mixture was immediately trans-
ferred to a quartz flat cell (RDC-60; 60 mm × 6m m× 0.3 mm,
Radical Research). The concentration of proteins in the final
reaction mixture was 250 µg/ml as evaluated according to the
method described previously (Bio-Rad Laboratories, Hercules,
CA). The ESR spectra were recorded by using a JEOL-TE X-band
spectrometer (JEOL, Tokyo, Japan). All ESR spectra were obtained
under the following conditions: 10 mW incident microwave
power, 100 kHz modulation frequency, 0.1 mT field modulation
amplitude and 15 mT scan range. Spectral computer simulation
were performed using a Win-Rad Radical Analyzer System
(Radical Research). All ESR spectra shown are representative of
at least three independent experiments.
Statistical analysis. The statistical significance of the data
was evaluated using analysis of variance (ANOVA) followed
by Duncan’s multiple range test. Statistical comparisons were
made using Scheffe’s method. A p value of <0.05 was considered
significant.
Results
Effects of lansoprazole against indomethacin induced
gastric cell damage. To examine the protective effect of
lansoprazole against indomethacin-induced cellular damage, we
undertook a cell viability assay in gastric epitherial RGM-1 cells,
which have no potential for acid secretion.
The exposure of RGM1 cells to 750 µM indomethacin for 18 h
caused a significant dose-related loss of cell viability, as determined
by the Tetra-Color ONE method (Fig. 1). The concentration of
indomethacin was decided according to previous preliminary
studies. Pretreatment with lansoprazole for 24 h before the indo-
methacin treatment significantly prevented the viability loss caused
by 750 µM indomethacin treatment. These results indicated that
lansoprazole has a protective effect against indomethacin-induced
cellular damage regardless of any acid secretion inhibitory effect.
Evaluation of lipid peroxidation by DPPP method. Lipid
peroxidation was involved in indomethacin-induced cellular injury.
To examine whether lansoprazole pretreatment reduces indo-
methacin-induced lipid peroxidation in gastric epithelial cells, we
pretreated RGM-1 cells with lansoprazole and examined lipid
peroxidation by detecting a fluorescent maker DPPP-oxide, a
specific marker of lipid peroxidation (Fig. 2). The fluorescence J. Clin. Biochem. Nutr. | July 2011 | vol. 49 | no. 1 | 27
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intensity of DPPP-oxide was significantly increased in indo-
methacin-treated cells compared to that in control cells. The fluo-
rescence intensity of DPPP oxide was significantly reduced in
lansoprazole-pretreated cells compared to indomethacin-alone-
treated cells, suggesting that lansoprazole pretreatment partly
inhibited indomethacin-induced lipid peroxidation in RGM1 cells.
Effects of lansoprazole against indomethacin induced
disruption of mitochondrial membrane potential. Disrup-
tion of mitochondrial membrane potential is involved in lipid
peroxidation induced by indomethacin treatment.(11) We hypo-
thesized that lansoprazole protected the disruption of mitochon-
drial membrane potential. We investigated mitochondrial
transmembrane potentials of indomethacin-treated RGM1 cells
pretreated with or without lansoprazole using a fluorescent
indicator JC-1. The results clearly indicate that the fluorescent
intensity significantly decreased in the indomethacin treated
cells, and that the lansoprazole pretreatment significantly inhibited
the decrease of the fluorescent intensity compared to that of indo-
methacin treated cells. These results suggest that lansoprazole pro-
tected against the disruption of mitochondrial membrane potentials
induced by indomethacin treatment (Fig. 3).
Determination of reactive oxygen species by electron spin
resonance. Disruption of mitochondrial membrane potential
by indomethacin treatment is accompanied with the release of
reactive oxygen species. We hypothesized indomethacin-induced
superoxide (O2￿−) leakage from mitochondria, because superoxide
is a major source of mitochondrial ROS leakage. To investigate
whether indomethacin treatment induced superoxide leakage
from mitochondria, we undertook ESR spectroscopy of isolated
mitochondria from indomethacin-treated RGM-1 cells by using a
spin-trapping reagent, CYPMPO. Furthermore, effects of lansopra-
zole pretreatment on superoxide leakage were investigated. The
mitochondria isolated from indomethacin treated RGM-1 cells
that were pretreated with or without lansoprazole were examined.
Incubation with respiratory substrates, the isolated mitochondria
showed ESR spectra of CYPMPO-OOH (Fig. 4). The ESR
spectrum parameters obtained from the mitochondria from the
cells treated with indomethacin alone were quite similar to those
of produced by the hypoxanthine (HX)/xanthine oxidase (XOD)
Fig. 1. Indomethacin induced cellular injury was measured by Tetra 
Color One method. The pretreatment of lansoprazole reduced cyto 
toxicityin a dose dependent (1, 10, 30 µM) manner and absorbance of
Tetra Color One was significantly higher than those of the un pretreated
group. The viability losses induced by 750 µM indomethacin were
38.7% ± 4.6%. Lansoprazole at 10 and 30 µM significantly inhibited the
reduction in cell viability, the inhibition being 14.2% at 10 µM and
14.4% at 30 µM, respectively, as determined by the Tetra Color One
assay method. On the other hand, the same amount of pretreatment of
omeprazole had no cytoprotective effect in this study. *p<0.05 vs
indomethacin 750 µM.
Fig. 2. The indomethacin induced cellular lipid peroxidation was measured with DPPP oxide fluorescence. Fluorescence intensity was measured
with a high sensitivity camera mounted epifluorescence microscope system. Cells with the indomethacin treatment emitted detectable DPPP fluo 




system and a simulation of CYPMPO-OOH adduct. The hyperfine
stricture constants (hfsc) of the spectrum agreed with that of the
computer-simulated spectrum of CYPMPO-OOH (data not shown).
Therefore, we concluded that the spectrum was assigned to the
CYPMPO-OOH spin adduct formed by the reaction of superoxide
with CYPMPO. The signal intensity of this ESR spectrum of the
mitochondria of the indomethacin-treated cells pretreated with
lansoprazole was considerably reduced in comparison to that of
the cells which were not pretreated with lansoprazole. These
results indicate that the mitochondria of the indomethacin-treated
RGM1 cells produced superoxide, while the pretreatment with
lansoprazole inhibited the production of superoxide.
Prevention of the indomethacin induced cellular injury in
MnSOD overexpressed cells. The superoxide production has
a key role in indomethacin-induced cellular damage, and previous
results demonstrated that lansoprazole reduced the production
of superoxide from mitochondria. We re-examined whether the
inhibition of mitochondrial superoxide production is involved in
the cytoprotective action of lansoprazole in indomethacin-induced
cellular injury by treating the gastric cells that overexpressed
MnSOD, which scavenges superoxide, with indomethacin and
lansoprazole. The MnSOD stable clones (MnSOD4, MnSOD6
and MnSOD8) and vector alone clone (Vector) were constructed,
and their activity was confirmed by native polyacrylamide gel
electrophoresis SOD activity analysis. It is noted that the SOD
activity of cytosolic copper zinc superoxide dismutase (Cu/ZnSOD),
which removes cytosolic superoxide, was not changed among the
clones (data not shown).
RGM1 cells that overexpressed MnSOD or vector cells were
pretreated with lansoprazole and treated with indomethacin and
their cellular damage was examined with previously-mentioned
methods. TC-1 analysis indicated that the cellular viability of
indomethacin-treated RGM1 vector cells was significantly
increased in the lansoprazole-pretreated group. On the other hand,
there were no significant effects of treatment with vs without
lansoprazole in MnSOD-overexpressed cells (Table 1). These
results suggest that the inhibition of mitochondrial superoxide
production is involved in the cytoprotective action of lansoprazole.
Discussion
In the presenting study we demonstrated that, for the first time
to our knowledge, treatment of lansoprazole inhibits the leakage of
superoxide from mitochondria, and subsequently protects against
Fig. 3. Mitochondrial membrane potentials were investigated with JC 
1. Fluorescence intensity was measured with plate reader DTX 880 at
18 h of 750 µM indomethacin treatments. The JC 1 fluorescence intensity
of cells without indomethacin treatment was significantly higher than
that of indomethacin treated cells. 24 h pretreatment of lansoprazole
protected mitochondrial membrane potentials at almost normal levels
(160.0 ± 29.0 vs 104.5 ± 26.3). *p<0.05 vs control.
Fig. 4. ESR spectrum (a) was obtained when aqueous solution containing isolated mitochondria from RGM1 cells with respiratory substrates and
10 mM CYPMPO was incubated for 5 min. ESR spectra (b) and (c) was obtained when aqueous solution containing indomethacin treated isolated
mitochondria with (b) or without (c) lansoprazole pretreatment from RGM1 cells with respiratory substrates and 10 mM CYPMPO was incubated for
5 min. ESR spectrum (d) was obtained when aqueous solution containing 250 µM hypoxanthine, 25 mU/ml hypoxanthine oxidase, 0.1 mM DATAPAC
and 10 mM CYPMPO was incubated for 5 min. ESR spectrum (e) was obtained when aqueous solution containing indomethacin treated isolated
mitochondria from MnSOD overexpressed RGM1 cells and 10 mM CYPMPO was incubated for 5 min. The ESR spectrum (f) was a computer simulated
ESR spectrum. The amount of ROS leakage from the mitochondria without indomethacin treated cells was significantly lower than that of
indomethacin treated cells. 24 h pretreatment of lansoprazole reduced this indomethacin induced ROS leakage by half. *p<0.05. J. Clin. Biochem. Nutr. | July 2011 | vol. 49 | no. 1 | 29
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the cellular lipid peroxidation and cell death induced by indo-
methacin in vitro.
In past studies the effectiveness of lansoprazole has been
examined by treating rodents with lansoprazole and NSAIDs in
vivo. However we have recently demonstrated that gastric acid by
itself induced the uncoupling of mitochondria, resulting in super-
oxide production and cellular lipid peroxidation. These results
suggest that the effects of lansoprazole treatment in in vivo studies
made it difficult to differentiate the effects due to acid suppression
from those not caused by acid suppression. We established an in
vitro study that was designed to allow the examination of the
effects of lansoprazole beyond acid suppression: we used gastric
epithelial RGM-1 cells that have no acid secretory ability and
treated them with lansoprazole to measure mitochondria injury,
superoxide generation, lipid peroxidation and cellular injury.
There is evidence that proton pump inhibitors, including
lansoprazole, have not only acid-suppression effects but also anti-
inflammatory effects beyond acid suppression: the expression of
CD11b/CD18 at the neutrophil, the induction of heme oxygenase-
1 in the gastric epithelial cells, the suppression of IL-8 production
in the gastric epithelial cells and the suppression of ICAM-1 and
VCAM-1 in the inner cells.(14–16) Moreover, it has been reported
that proton pump inhibitors have a suppressive effect of reactive
oxygen species in the neutrophil.(17) It was reported that omepra-
zole has a cytoprotective effect beyond acid suppression; however,
the same dose of omeprazole was not able to protect against
cellular injury in this study. The reason why the omeprazole was
not able to protect against cellular injury by indomethacin is
unknown, but there is a possibility that lansoprazole has a stronger
cytoprotective effect than omeprazole. Indeed, an in vivo study
recently demonstrated that lansoprazole, but not omeprazole,
protected against an indomethacin-induced small intestine ulcer.
NSAIDs cause gastrointestinal injury through both topical and
systemic effects. The systemic effects of NSAIDs have been well
studied from the early 1970s, and the studies show that the
reduction in prostaglandin biosynthesis is insufficient to explain
fully the pathogenesis of NSAIDs-induced ulcers.(7) Several
studies show that reagents which have antioxidant potential were
effective in preventing NSAIDs-induced ulcers.(18,19) These results
indicate that prostaglandin-independent mechanisms are important,
and that, furthermore, decreasing ROS is effective in NSAIDs-
induced ulcer. ROS probably directly oxidizes cellular proteins,
lipids or nucleic acids and causes general damage or dysfunction,
and probably initiates the cell death process through affecting
various signaling cascades leading to necrosis and apoptosis.(20)
We elucidated that lansoprazole directly inhibits NSAIDs-induced
ROS production and its derived cytotoxic reaction.
In the present study we did not show the effects of lansoprazole
on PGE2 production. However, since treatment of PGE2 did not
affect the injury of the mitochondria, we concluded the lansopra-
zole would not inhibit the pathway of the ROS generation from
mitochondria by PGE2 production. In previous studies lansopra-
zole administration did not significantly modify prostaglandin
release in gastric juice in rat models.(21,22) Moreover, lansoprazole
does not influence the down-regulation of gastric prostaglandin
production associated with NSAID treatment.(6) Therefore, lanso-
prazole does not appear to exert a positive influence on gastric
PGE2 levels by NSAID treatment.
Gastric cellular lipid peroxidation has been regarded as an
important prime event that leads to gastric mucosal injuries, and
our previous study demonstrated that NSAIDs induced intrinsic,
mitochondria-derived ROS, which evokes cellular peroxidation.
Moreover, NSAIDs uncouple mitochondrial oxidative phosphory-
lation and inhibit the electron transport chain. This results in re-
duction of gastric mucosal ATP, induction of Ca2+ signaling and
generation of ROS-like superoxide and hydroxyl radicals.(8–10)
However, it has been difficult to trap the superoxide stably. The
formerly-used spin traps such as DMPO have a short half life for
the superoxide adduct. CYPMPO can more efficiently trap super-
oxide compared with DMPO because it has lower cytotoxicity and
its superoxide adduct has a longer lifetime.(23) We trapped the
superoxide from the indomethacin-treated mitochondria by using
CYPMPO in ESR. These results were in agreement with our
previous study that indomethacin causes lipid peroxidation by the
superoxide from mitochondria.
In the present study, lansoprazole treatment reduced the super-
oxide from indomethacin-treated mitochondria. The exact mecha-
nisms that caused lansoprazole to reduce the superoxide leakage
from mitochondria remain to be fully elucidated; it seems probable
that scavenging of the superoxide from indomethacin-treated
mitochondria prevented lipid peroxidation. We also demonstrated
that lansoprazole pretreated RGM1-vector cells were more efficient
at protecting against indomethacin-induced cellular injury than
MnSOD-overexpressed cells. These results suggest lansoprazole
is not irrelevant to MnSOD.
In conclusion, this study demonstrated that lansoprazole reduced
superoxide production in mitochondria of indomethacin treated
cells, and subsequently inhibited lipid peroxide and cellular injury
in gastric epithelial cells. The results provide biological evidence
for effects beyond acid suppression of lansoprazole, and we expect
that these findings will also be applicable in NSAIDs-induced
small-intestinal ulcer which is independent from acid exposure.
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Cu/ZnSOD copper zinc superoxide dismutase
DPPP Diphenyl-1pyrenylphosphine
ESR electron spin resonance
H2RAs H2-receptor antagonists
Hfsc hyperfine stricture constants
HX hypoxanthine
MnSOD manganese superoxide dismutase
NSAIDs non-steroidal anti-inflammatory drugs
PBS phosphate buffered saline
PGE2 prostaglandin  E2
PPIs proton pump inhibitors
ROS reactive oxygen species
XOD xanthine oxidase
Table 1. Cell viability in manganese superoxide dismutase (MnSOD) 
overexpressed cells
There were no significant effects of treatment with vs without
lansoprazole in terms of cellular viability. mean ± SD, *p<0.05 vs lanso 
prazole (–).
Cell viability (%)
Lansoprazole (–) Lansoprazole (+)
RGM1 26.5 ± 0.2 34.0 ± 0.1*
MnSOD4 64.5 ± 0.2 58.0 ± 0.8
MnSOD6 60.1 ± 0.5 65.7 ± 0.4
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